

April 1, 2022

News Release

Company: Olympus Corporation
Yasuo Takeuchi, Director, Representative Executive Officer, President and CEO
(Code: 7733, First Section, Tokyo Stock Exchange)
Contact: Takaaki Sakurai, Vice President, Investor Relations
TEL: +81-3-3340-2111

(Progress of Disclosure Matters) Notice Concerning Complete of Reorganization of Scientific Solutions Business through Company Split (Simple Absorption-type Split)

As announced on December 17, 2021 in the "Notice Concerning Reorganization of Scientific Solutions Business through Company Split (Simple Absorption-type Split)," Olympus Corporation ("Olympus") decided to implement a company split (the "Company Split") under which the newly established wholly owned subsidiary, Evident Corporation ("Evident") takes over our scientific business. Today, Olympus has completed the Company Split as announced. as following.

1. Items and book values of assets and liabilities to be split (non-consolidated) (Note 1)

a. Assets (Book value)

Current assets	JPY 136,026 million	(Note 2)
Fixed assets	JPY 7,240 million	
Total	JPY 143,265 million	

b. Liabilities (Book value)

Current liabilities	JPY 901 million
Fixed liabilities	JPY 338 million
Total	JPY 1,239 million

(Note 1) The above are estimated amounts calculated based on the forecast of the balance sheet on March 31, 2022. Each amount may have varied since the above date and the actual amounts may differ from the above amounts.

(Note 2) Current assets to be split off mainly consist of cash and deposits to be used for reorganization and working capital.

2. Operating results of the divisions to succeed (Consolidated)

Earnings Forecasts for the Fiscal Year Ending March 31, 2022 (released on February 4, 2022)

Revenue	JPY 114,000 million
Operating profit	JPY 15,500 million


3. Status after the corporate split

	Successor company
1) Name	Evident Corporation
2) Head Office Functions	2-3-1, Nishi-Shinjuku, Shinjuku-ku, Tokyo
3) Head office	6666 Inatomi, Tatsuno-machi, Kamiina-gun, Nagano
4) Job Title/Name of Representative	Yoshitake Saito, President and Representative Director
5) Description of Businesses	Businesses related to the development, manufacture, sale and provision of solutions for biological microscopes, industrial microscopes, industrial endoscopes, non-destructive testing equipment, and X-ray analyzers, etc.
6) Capital	JPY 0.5 million (As of April 1, 2022)
7) Fiscal year end	March 31

(Reference) Reorganization within the Olympus group related to the split of the Scientific Solutions Business

Upon the company split, the assets and rights and obligations of the Olympus' domestic and overseas subsidiaries concerning the Scientific Solutions Business will also be inherited by Evident. The Evident's global entity structure after the reorganization within the Olympus group is as follows, with details omitted.

Evident Global Entity Structure



(Note 3) Currently, we have suspended sales activities of the Scientific Solutions Business in Russia. As a result, the transfer procedure of subsidiary in Russia has also postponed. The measures will be kept under continuous review.